IREN proposes $875 million convertible notes offering due 2031
Bobak R. Azamian, President, CEO and Board Chair at Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), sold 6,000 shares of common stock on September 24, 2025, for a total value of $332220. The transaction comes as TARS trades near its 52-week high of $59.76, having delivered an impressive 67% return over the past year. According to InvestingPro analysis, the company maintains a GOOD financial health score of 2.8.
The shares were sold at a weighted average price of $55.37, in multiple transactions at prices ranging from $55.19 to $55.93. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2024. Following the transaction, Azamian directly owns 53,635 shares and indirectly owns 812,106 shares through The Bobak Azamian Living Trust. For deeper insights into TARS’s valuation and 10+ additional ProTips, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Tarsus Pharmaceuticals announced its Q2 2025 earnings, reporting a revenue of $102.7 million, which surpassed analysts’ forecasts of $95.68 million. However, the company reported an earnings per share (EPS) of -$0.48, falling short of the expected -$0.38. Despite the EPS miss, the company experienced a positive market reaction, attributed to its strong revenue performance and optimistic forward guidance. These developments highlight the company’s ability to exceed revenue expectations while facing challenges in meeting EPS forecasts. Investors and analysts are likely to focus on how Tarsus Pharmaceuticals plans to address the EPS shortfall in future quarters. The recent earnings report underscores the importance of revenue performance in driving investor sentiment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.